Insmed logo

Insmed Share Price Today

(NASDAQ: INSM)

Insmed share price is $76.29 & ₹6,606.14 as on 31 Jan 2025, 2.30 'hrs' IST

$76.29

-1.71

(-2.19%)

Market is closed - opens 8 PM, 31 Jan 2025

View live Insmed share price in Dollar and Rupees. Guide to invest in Insmed stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Insmed, along with analyst recommendations, forecasts, and comprehensive financials.

Insmed share price movements

  • Today's Low: $75.66
    Today's High: $80.36

    Day's Volatility :5.85%

  • 52 Weeks Low: $21.92
    52 Weeks High: $80.53

    52 Weeks Volatility :72.78%

Insmed (INSM) Returns

PeriodInsmed IncorporatedSector (Health Care)Index (Russel 2000)
3 Months
14.17%
-1.7%
0.0%
6 Months
8.62%
-3.0%
0.0%
1 Year
173.4%
3.6%
0.0%
3 Years
228.98%
11.6%
-10.1%

Insmed (INSM) Key Statistics

in dollars & INR

Previous Close
$78.0
Open
$78.8
Today's High
$80.36
Today's Low
$75.66
Market Capitalization
$14.0B
Today's Volume
$967.2K
52 Week High
$80.53
52 Week Low
$21.92
Revenue TTM
$343.0M
EBITDA
$-695.1M
Earnings Per Share (EPS)
$-5.55
Profit Margin
-252.01%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-890.75%

How to invest in Insmed Stock (INSM) from India?

It is very easy for Indian residents to invest directly in Insmed from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Insmed stock in both Indian Rupees (INR) and US Dollars (USD). Search for Insmed or INSM on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Insmed or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Insmed shares which would translate to 0.011 fractional shares of Insmed as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Insmed, in just a few clicks!

Returns in Insmed (INSM) for Indian investors in Rupees

The Insmed stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Insmed investment value today

Current value as on today

₹2,71,693

Returns

₹1,71,693

(+171.69%)

Returns from Insmed Stock

₹1,67,403 (+167.4%)

Dollar Returns

₹4,291 (+4.29%)

Indian investors sentiment towards Insmed (INSM)

-26%

Period: Dec 31, 2025 to Jan 30, 2025. Change in 30 Days versus previous period

Search interest for Insmed Stock from India on INDmoney has decreased by -26% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Insmed

  • Vanguard Group Inc

    9.58%

  • BlackRock Inc

    8.37%

  • T. Rowe Price Associates, Inc.

    7.03%

  • Darwin Global Management, Ltd.

    5.87%

  • FMR Inc

    4.02%

  • Capital Research & Mgmt Co - Division 3

    3.65%

Analyst Recommendation on Insmed

Buy

    95%Buy

    4%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Insmed(by analysts ranked 0 to 5 stars)

Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
22
21
19
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Insmed Stock (INSM)

What analysts predicted

Upside of 15.53%

Target:

$88.14

Current:

$76.29

Insights on Insmed Stock (Ticker Symbol: INSM)

  • Price Movement

    In the last 1 year, INSM stock has moved up by 169.2%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 75.5M → 93.42M (in $), with an average increase of 9.9% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -300.60M → -220.52M (in $), with an average increase of 36.3% per quarter

INSM Insmed Financials in INR & Dollars

FY18Y/Y Change
Revenue
$9.8M
-
Net Income
$-324.3M
↑ 68.33%
Net Profit Margin
-3.3K%
-
FY19Y/Y Change
Revenue
$136.5M
↑ 1287.56%
Net Income
$-254.3M
↓ 21.57%
Net Profit Margin
-186.37%
↑ 3110.8%
FY20Y/Y Change
Revenue
$164.4M
↑ 20.48%
Net Income
$-294.1M
↑ 15.63%
Net Profit Margin
-178.87%
↑ 7.5%
FY21Y/Y Change
Revenue
$188.5M
↑ 14.63%
Net Income
$-434.7M
↑ 47.8%
Net Profit Margin
-230.63%
↓ 51.76%
FY22Y/Y Change
Revenue
$245.4M
↑ 30.19%
Net Income
$-481.5M
↑ 10.79%
Net Profit Margin
-196.26%
↑ 34.37%
FY23Y/Y Change
Revenue
$305.2M
↑ 24.39%
Net Income
$-749.6M
↑ 55.66%
Net Profit Margin
-245.59%
↓ 49.33%
Q2 FY23Q/Q Change
Revenue
$77.2M
↑ 18.42%
Net Income
$-244.8M
↑ 53.23%
Net Profit Margin
-316.99%
↓ 72.01%
Q3 FY23Q/Q Change
Revenue
$79.1M
↑ 2.39%
Net Income
$-158.9M
↓ 35.08%
Net Profit Margin
-201.0%
↑ 115.99%
Q4 FY23Q/Q Change
Revenue
$83.7M
↑ 5.84%
Net Income
$-186.1M
↑ 17.07%
Net Profit Margin
-222.31%
↓ 21.31%
Q1 FY24Q/Q Change
Revenue
$75.5M
↓ 9.79%
Net Income
$-157.1M
↓ 15.57%
Net Profit Margin
-208.07%
↑ 14.24%
Q2 FY24Q/Q Change
Revenue
$90.3M
↑ 19.66%
Net Income
$-300.6M
↑ 91.36%
Net Profit Margin
-332.75%
↓ 124.68%
Q3 FY24Q/Q Change
Revenue
$93.4M
↑ 3.41%
Net Income
$-220.5M
↓ 26.64%
Net Profit Margin
-236.04%
↑ 96.71%
FY18Y/Y Change
Profit
$7.4M
↓ 355.5%
FY19Y/Y Change
Profit
$112.3M
↑ 1414.5%
FY20Y/Y Change
Profit
$124.5M
↑ 10.94%
FY21Y/Y Change
Profit
$144.3M
↑ 15.87%
FY22Y/Y Change
Profit
$190.2M
↑ 31.82%
FY23Y/Y Change
Profit
$239.6M
↑ 25.97%
Q2 FY23Q/Q Change
Profit
$60.6M
↑ 18.0%
Q3 FY23Q/Q Change
Profit
$62.4M
↑ 2.85%
Q4 FY23Q/Q Change
Profit
$65.3M
↑ 4.62%
Q1 FY24Q/Q Change
Profit
$56.8M
↓ 12.98%
Q2 FY24Q/Q Change
Profit
$68.1M
↑ 19.96%
Q3 FY24Q/Q Change
Profit
$72.3M
↑ 6.08%
FY18Y/Y Change
Operating Cash Flow
$-258.0M
↑ 61.62%
Investing Cash Flow
$-14.8M
↑ 393.64%
Financing Cash Flow
$386.7M
↑ 1.48%
FY19Y/Y Change
Operating Cash Flow
$-250.6M
↓ 2.84%
Investing Cash Flow
$-42.3M
↑ 185.32%
Financing Cash Flow
$285.3M
↓ 26.24%
FY20Y/Y Change
Operating Cash Flow
$-219.3M
↓ 12.49%
Investing Cash Flow
$-6.8M
↓ 83.86%
Financing Cash Flow
$271.0M
↓ 5.0%
FY21Y/Y Change
Operating Cash Flow
$-363.3M
↑ 65.63%
Investing Cash Flow
$-64.3M
↑ 842.32%
Financing Cash Flow
$612.5M
↑ 126.03%
FY22Y/Y Change
Operating Cash Flow
$-400.4M
↑ 10.22%
Investing Cash Flow
$-34.6M
↓ 46.2%
Financing Cash Flow
$793.3M
↑ 29.5%
Q2 FY23Q/Q Change
Operating Cash Flow
$-122.8M
↓ 16.07%
Investing Cash Flow
$-274.2M
↓ 759.0%
Financing Cash Flow
$44.3M
↓ 11209.27%

Insmed Technicals Summary

Sell

Neutral

Buy

Insmed is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Insmed (INSM) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Insmed Incorporated logo
11.51%
8.62%
173.4%
228.98%
170.08%
Biontech Se logo
6.33%
47.74%
28.2%
-32.54%
300.26%
Regeneron Pharmaceuticals, Inc. logo
-3.52%
-36.49%
-28.24%
12.05%
101.47%
Vertex Pharmaceuticals Incorporated logo
9.64%
-10.71%
1.76%
79.73%
91.54%
Alnylam Pharmaceuticals, Inc. logo
16.44%
0.71%
56.64%
89.05%
138.96%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Insmed Incorporated logo
NA
NA
0.0
-5.35
-8.91
-0.26
NA
2.7
Biontech Se logo
160.8
NA
0.04
-3.32
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
16.98
16.98
1.06
45.11
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.16
0.48
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Insmed Incorporated logo
Buy
$14.0B
170.08%
NA
-252.01%
Biontech Se logo
Buy
$29.8B
300.26%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$75.4B
101.47%
16.98
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$113.5B
91.54%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$36.0B
138.96%
NA
-15.86%

Insmed Dividend announcements

  • Insmed Earnings

    Insmed’s price-to-earnings ratio stands at None

    Read More

About Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Organization
Insmed
Employees
912
CEO
Mr. William H. Lewis J.D., M.B.A.
Industry
Health Technology

Management People of Insmed

NameTitle
Mr. William H. Lewis J.D., M.B.A.
President, CEO & Chairman
Ms. Sara M. Bonstein M.B.A.
Chief Financial Officer
Mr. Roger Adsett M.B.A.
Chief Operating Officer
Mr. John Drayton Wise M.B.A.
Chief Commercial Officer
Dr. Martina Flammer M.B.A., M.D.
Chief Medical Officer
Mr. Brian K. Kaspar Ph.D.
Chief Scientific Officer
Ms. Eleanor Barisser
Associate Director of Investor Relations
Mr. Michael Alexander Smith J.D.
Chief Legal Officer & Corporate Secretary
Mandy Fahey
Executive Director of Corporate Communications
Ms. S. Nicole Schaeffer M.B.A.
Chief People Strategy Officer

Important FAQs about investing in INSM Stock from India :

What is Insmed share price today?

Insmed share price today stands at $76.29, Open: $78.80 ; Previous Close: $78.00 ; High: $80.36 ; Low: $75.66 ; 52 Week High: $80.53 ; 52 Week Low: $21.92.

The stock opens at $78.80, after a previous close of $78.00. The stock reached a daily high of $80.36 and a low of $75.66, with a 52-week high of $80.53 and a 52-week low of $21.92.

Can Indians buy Insmed shares?

Yes, Indians can invest in the Insmed (INSM) from India.

With INDmoney, you can buy Insmed at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Insmed at zero transaction cost.

How can I buy Insmed shares from India?

It is very easy to buy Insmed from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Insmed (INSM) be purchased?

Yes, you can buy fractional shares of Insmed with INDmoney app.

What are the documents required to start investing in Insmed stocks?

To start investing in Insmed, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Insmed Stock (INSM)?

Today’s highest price of Insmed (INSM) is $80.36.

Today’s lowest price of Insmed (INSM) is $75.66.

What is today's market capitalisation of Insmed?

Today's market capitalisation of Insmed INSM is 14.0B

What is the 52 Week High and Low Range of Insmed Stock (INSM)?

  • 52 Week High

    $80.53

  • 52 Week Low

    $21.92

What are the historical returns of Insmed (INSM)?

  • 1 Month Returns

    11.51%

  • 3 Months Returns

    8.62%

  • 1 Year Returns

    173.4%

  • 5 Years Returns

    170.08%

Who is the Chief Executive Officer (CEO) of Insmed ?

Mr. William H. Lewis J.D., M.B.A. is the current Chief Executive Officer (CEO) of Insmed.